Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 2
1951 1
1953 4
1954 1
1955 1
1956 3
1957 2
1958 1
1959 3
1960 1
1961 1
1962 3
1963 3
1964 5
1965 2
1966 10
1967 4
1968 18
1969 10
1970 12
1971 26
1972 35
1973 47
1974 58
1975 159
1976 170
1977 168
1978 219
1979 214
1980 202
1981 186
1982 177
1983 234
1984 256
1985 291
1986 248
1987 321
1988 397
1989 440
1990 478
1991 510
1992 605
1993 685
1994 737
1995 939
1996 1006
1997 1155
1998 1182
1999 1428
2000 1573
2001 1710
2002 1859
2003 2092
2004 2258
2005 2474
2006 2873
2007 3085
2008 3292
2009 3633
2010 4065
2011 4588
2012 4939
2013 5614
2014 6334
2015 6827
2016 6965
2017 7144
2018 7605
2019 8343
2020 9211
2021 9555
2022 8552
2023 8379
2024 3810

Text availability

Article attribute

Article type

Publication date

Search Results

123,270 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "No progression to cancer"
Page 1
Pancreatic Cancer: Pathogenesis and Diagnosis.
Goral V. Goral V. Asian Pac J Cancer Prev. 2015;16(14):5619-24. doi: 10.7314/apjcp.2015.16.14.5619. Asian Pac J Cancer Prev. 2015. PMID: 26320426 Free article. Review.
Its frequency is gradually increasing over the past years. It accounts for 2% of all cancers and 5% of cancer-related deaths. Pancreatic cancer takes the first place among asymptomatic cancers. ...Pancreatic cancer may result from hereditary ger …
Its frequency is gradually increasing over the past years. It accounts for 2% of all cancers and 5% of cancer-related deaths. …
Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.
Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauß A, Blaudszun AR, Yevsa T, Fricke S, Kossatz-Boehlert U. Walcher L, et al. Front Immunol. 2020 Aug 7;11:1280. doi: 10.3389/fimmu.2020.01280. eCollection 2020. Front Immunol. 2020. PMID: 32849491 Free PMC article. Review.
The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest over the last decades. In particular, the analysis of biomarkers in cancer patients within the pre- and post-therapeutic period is required to identify several types of cells, which ca …
The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest over the last decades. In particular, the analysis …
Role of interleukin-6 in cancer progression and therapeutic resistance.
Kumari N, Dwarakanath BS, Das A, Bhatt AN. Kumari N, et al. Tumour Biol. 2016 Sep;37(9):11553-11572. doi: 10.1007/s13277-016-5098-7. Epub 2016 Jun 3. Tumour Biol. 2016. PMID: 27260630 Review.
The principal cause behind limitations in the curability of this disease is the reducing sensitivity of the cancer cells towards conventional anticancer therapeutic modalities, particularly in advance stages of the disease. ...The strong association between i …
The principal cause behind limitations in the curability of this disease is the reducing sensitivity of the cancer cells towar …
MicroRNA: A signature for cancer progression.
Hussen BM, Hidayat HJ, Salihi A, Sabir DK, Taheri M, Ghafouri-Fard S. Hussen BM, et al. Biomed Pharmacother. 2021 Jun;138:111528. doi: 10.1016/j.biopha.2021.111528. Epub 2021 Mar 23. Biomed Pharmacother. 2021. PMID: 33770669 Free article. Review.
MicroRNAs (miRNAs) are a group of small non-coding RNAs that post-transcriptionally control expression of genes by targeting mRNAs. miRNA alterations partake in the establishment and progression of different types of human cancer. Consequently, expression profiling …
MicroRNAs (miRNAs) are a group of small non-coding RNAs that post-transcriptionally control expression of genes by targeting mRNAs. miRNA al …
Intratumoral heterogeneity in cancer progression and response to immunotherapy.
Vitale I, Shema E, Loi S, Galluzzi L. Vitale I, et al. Nat Med. 2021 Feb;27(2):212-224. doi: 10.1038/s41591-021-01233-9. Epub 2021 Feb 11. Nat Med. 2021. PMID: 33574607 Review.
Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed by trophic, metabolic, immunological, and therapeutic factors. ...Here, we discuss the main sources of intratumoral heterogeneity and its impact on the natural history of the disea …
Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed by trophic, metabolic, immunological, and t …
Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment.
Mansinho A, Macedo D, Fernandes I, Costa L. Mansinho A, et al. Adv Exp Med Biol. 2018;1096:117-133. doi: 10.1007/978-3-319-99286-0_7. Adv Exp Med Biol. 2018. PMID: 30324351 Review.
Prostate cancer is the most common malignancy in men, and remains the second leading cause of cancer-related death in this gender [1]. ...Additionally, patients with non-metastatic CRPC are at higher risk of disease progression. Approximately 15-33% of …
Prostate cancer is the most common malignancy in men, and remains the second leading cause of cancer-related death in this gen …
Hyperprogression under Immunotherapy.
Frelaut M, Le Tourneau C, Borcoman E. Frelaut M, et al. Int J Mol Sci. 2019 May 30;20(11):2674. doi: 10.3390/ijms20112674. Int J Mol Sci. 2019. PMID: 31151303 Free PMC article. Review.
Immunotherapy is now widely prescribed in oncology, leading to the observation of new types of responses, including rapid disease progression sometimes reported as hyperprogression. However, only a few studies have assessed the question of hyperprogression and there …
Immunotherapy is now widely prescribed in oncology, leading to the observation of new types of responses, including rapid disease …
Melanoma: BRAFi Rechallenge.
Kosmidis CS, Papadopoulou K, Mystakidou CM, Papadopoulou E, Mantalovas S, Varsamis N, Koulouris C, Theodorou V, Papadopoulos K, Sevva C, Miltiadous P, Petanidis S, Georgakoudi E, Papadopoulou E, Baka S. Kosmidis CS, et al. Medicina (Kaunas). 2023 May 18;59(5):975. doi: 10.3390/medicina59050975. Medicina (Kaunas). 2023. PMID: 37241207 Free PMC article.
The patient underwent surgery and received additional targeted therapy as part of a clinical study. In subsequent disease progression, immunotherapy was used. When the disease progressed again while the patient was in a good performance status, targete …
The patient underwent surgery and received additional targeted therapy as part of a clinical study. In subsequent disease progress …
Bladder cancer.
Bischoff CJ, Clark PE. Bischoff CJ, et al. Curr Opin Oncol. 2009 May;21(3):272-7. doi: 10.1097/cco.0b013e328329f184. Curr Opin Oncol. 2009. PMID: 19370808 Review.
Transurethral resection and instillation of perioperative chemotherapy remains the treatment of choice for superficial bladder cancer in most patients. Data supports the use of intravesical Bacillus Calmette-Guerin (including a maintenance regimen) for those at high risk f …
Transurethral resection and instillation of perioperative chemotherapy remains the treatment of choice for superficial bladder cancer …
Clinical and translational relevance of intratumor heterogeneity.
Goyette MA, Lipsyc-Sharf M, Polyak K. Goyette MA, et al. Trends Cancer. 2023 Sep;9(9):726-737. doi: 10.1016/j.trecan.2023.05.001. Epub 2023 May 27. Trends Cancer. 2023. PMID: 37248149 Review.
Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH …
Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made …
123,270 results
You have reached the last available page of results. Please see the User Guide for more information.